Trends in kidney transplantation over the past decade

Drugs

Volumn 68, Issue SUPPL. 1, 2008, Pages 3-10

  Knoll, Greg ^a,b,c  

^a UNIVERSITY OF OTTAWA   (Canada)

^b OTTAWA HOSPITAL RESEARCH INSTITUTE   (Canada)

^c UNIVERSITY OF OTTAWA   (Canada)

Author keywords

Renal transplant

Indexed keywords

AZATHIOPRINE; BASILIXIMAB; CALCINEURIN INHIBITOR; CYCLOSPORIN A; DACLIZUMAB; MYCOPHENOLIC ACID; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; TACROLIMUS; THYMOCYTE ANTIBODY;

CANADA; CARDIOVASCULAR DISEASE; CHRONIC ALLOGRAFT NEPHROPATHY; GRAFT FAILURE; GRAFT SURVIVAL; HEART DEATH; HOSPITAL ADMISSION; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; INFECTION; KIDNEY DONOR; KIDNEY FAILURE; KIDNEY TRANSPLANTATION; NEOPLASM; QUALITY OF LIFE; REVIEW; UNITED STATES;

AGE FACTORS; CANADA; GRAFT SURVIVAL; HUMANS; IMMUNOSUPPRESSIVE AGENTS; KIDNEY FAILURE, CHRONIC; KIDNEY TRANSPLANTATION; SURVIVAL RATE; TIME FACTORS; TISSUE AND ORGAN PROCUREMENT; UNITED STATES; WAITING LISTS;

EID: 42649096927     PISSN: 00126667     EISSN: 00126667     Source Type: Journal    
DOI: 10.2165/00003495-200868001-00002     Document Type: Review

References (31)

1. Grassmann A, Gioberge S, Moeller S, et al. ESRD patients in 2004: global overview of patient numbers, treatment modalities and associated trends. Nephrol Dial Transplant 2005 Dec; 20 (12): 2587-93
2. Wolfe RA, Ashby VB, Milford EL, et al. Comparison of mortality in all patients on dialysis, patients on dialysis awaiting transplantation, and recipients of a first cadaveric transplant. N Engl J Med 1992 Dec 2; 341 (23): 1725-30
3. U.S. Renal Data System, USRDS 2006 Annual Data Report. Atlas of end-stage renal disease in the United States. Bethesda (MD): National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Diseases, 2006 [online]. Available from URL: http://www.usrds.org/adr.htm [Accessed 2007 May 10]
4. Laupacis A, Keown P, Pus N, et al. A study of the quality of life and cost-utility of renal transplantation. Kidney Int 1996 Jul; 50 (1): 235-42
5. Canadian Organ Replacement Register (CORR), 2005. e-Statistics report on transplant, waiting list and donor statistics. 2005 summary statistics, January 1 to December 31, 2005. Ottawa: The Society; 2005 [online]. Available from URL: http://secure.cihi.ca/cihiweb/dispPage.jsp?cw_page=reports_corrstats2005c_e [Accessed 2007 Feb 2]
6. Organ Procurement and Transplantation Network and the Scientific Registry of Transplant Recipients (OPTN/SRTR), 2006. 2006 OPTN/SRTR Annual Report. The U.S. Organ Procurement and Transplantation Network and the Scientific Registry of Transplant Recipients [online]. Available from URL: http://www.ustransplant. org/annual_reports/current/default.htm [Accessed 2007 Mar 6]
7. UNOS. Organ distribution: allocation of deceased kidneys. UNOS Policy 3.5.1. Definition of expanded criteria donor and standard donor. Richmond (VA): United Network for Organ Sharing, 2006 [online]. Available from URL: http://www.unos.org [Accessed 2007 Sep 14]
8. Organ Procurement and Transplantation Network and the Scientific Registry of Transplant Recipients [OPTN/SRTR], 2005. 2005 OPTN/SRTR Annual Report. The U.S. Organ Procurement and Transplantation Network and the Scientific Registry of Transplant Recipients [online]. Available from URL: http://www.ustransplant. org/annual_reports/current/default.htm [Accessed 2007 Jan 6]
9. Lunsford SL, Simpson KS, Chavin KD, et al. Racial disparities in living kidney donation: is there a lack of willing donors or an excess of medically unsuitable candidates? Transplantation 2006; 82 (7): 876-81
10. Meier-Kriesche HU, Schold JD, Gaston RS, et al. Kidneys from deceased donors: maximizing the value of a scarce resource. Am J Transplant 2005 Jul; 5 (7): 1725-30
11. Ojo AO. Expanded criteria donors: process and outcomes. Semin Dial 2005 Nov-Dec; 18 (6): 463-8
12. Webster AC, Lee VW, Chapman JR, et al. Target of rapamycin inhibitors (TOR-I; sirolimus and everolimus) for primary immunosuppression in kidney transplant recipients. Cochrane Database Syst Rev 2006 Apr; 19 (2): CD004290
13. Srinivas TR, Schold JD, Guerra G, et al. Mycophenolate mofetil/sirolimus compared to other common immunosuppressive regimens in kidney transplantation. Am J Transplant 2007 Mar; 7 (3): 586-94
14. Adams PL. Long-term patient survival: strategies to improve overall health. Am J Kidney Dis 2006 Apr; 47 (4 Suppl. 2): S65-85
15. Kasiske BL, Snyder JJ, Gilbertson DT, et al. Cancer after kidney transplantation in the United States. Am J Transplant 2004 Jun; 4 (6): 905-13
16. Kasiske BL, Israni AK. Strategies to prevent ischemic heart disease after kidney transplantation. Transplant Rev 2006 Jan; 20 (1): 19-27
17. Holdaas H, Fellstrom B, Jardine AG, et al. Assessment of LEscol in Renal Transplantation (ALERT) Study Investigators. Effect of fluvastatin on cardiac outcomes in renal transplant recipients: a multicentre, randomised, placebo-controlled trial. Lancet 2003 Jun 14; 361 (9374): 2024-31
18. Vajdic CM, McDonald SP, McCredie MR, et al. Cancer incidence before and after kidney transplantation. JAMA 2006 Dec 20; 296 (23): 2823-31
19. Buell JF, Gross TG, Woodle ES. Malignancy after transplantation. Transplantation 2005 Oct 15; 80 (2 Suppl.): S254-64
20. Andrassy J, Graeb C, Rentsch M, et al. mTOR inhibition and its effect on cancer in transplantation. Transplantation 2005 Sep 27; 80 (1 Suppl.): S171-4
21. Luan FL, Hojo M, Maluccio M, et al. Rapamycin blocks tumor progression: unlinking immunosuppression from antitumor efficacy. Transplantation 2002 May 27; 73 (10): 1565-72
22. Guba M, von Breitenbuch P, Steinbauer M, et al. Rapamycin inhibits primary and metastatic tumor growth by antiangiogenesis: involvement of vascular endothelial growth factor. Nat Med 2002 Feb; 8 (2): 128-35
23. Campistol JM, Gutierrez-Dalmau A, Torregrosa JV. Conversion to sirolimus: a successful treatment for posttransplantation Kaposi's sarcoma. Transplantation 2004 Mar 15; 77 (5): 760-2
24. Stallone G, Schena A, Infante B, et al. Sirolimus for Kaposi's sarcoma in renal-transplant recipients. N Engl J Med 2005 Mar 31; 352 (13): 1317-23
25. Garcia VD, Bonamigo Filho JL, Neumann J, et al. Rituximab in association with rapamycin for post-transplant lymphoproliferative disease treatment. Transpl Int 2003 Mar; 16 (3): 202-6
26. Sierka K, Kumar MSA, Heifets M, et al. Successful minimization of immunosuppression (IM) and conversion to sirolimus (SLR) in kidney transplants recipients with post transplant lymphoproliferative disease (PTLD) and de novo nonskin malignancies (DNSM) [abstract no. 1331]. Am J Transplant 2004 Mar; 4 Suppl. 8: 523
27. Mathew T, Kreis H, Friend P. Two-year incidence of malignancy in sirolimus-treated renal transplant recipients: results from five multicenter studies. Clin Transplant 2004 Aug; 18 (4): 446-9
28. Kahan BD, Yakupoglu YK, Schoenberg L, et al. Low incidence of malignancy among sirolimus/cyclosporine-treated renal transplant recipients. Transplantation 2005 Sep 27; 80 (6): 749-58
29. Campistol JM, Eris J, Oberbauer R, et al. Sirolimus therapy after early cyclosporine withdrawal reduces the risk for cancer in adult renal transplantation. J Am Soc Nephrol 2006 Feb; 17 (2): 581-9
30. Kauffman HM, Cherikh WS, Cheng Y, et al. Maintenance immunosuppression with target-of-rapamycin inhibitors is associated with a reduced incidence of de novo malignancies. Transplantation 2005 Oct 15; 80 (7): 883-9
31. Atkins MB, Hidalgo M, Stadler WM, et al. Randomized phase II study of multiple dose levels of CCI-779, a novel mammalian target of rapamycin kinase inhibitor, in patients with advanced refractory renal cell carcinoma. J Clin Oncol 2004 Mar 1; 22 (5): 909-18